Administration of RGFP-966, a pharmacological inhibitor of the enzyme histone deacetylase 3 (HDAC3), to a transgenic mouse model of Alzheimer's disease (AD) reduced amyloid-beta in vulnerable brain regions, increased plasma levels of an amyloid-beta-degrading enzyme, reversed tau protein phosphorylation at disease-relevant sites, and improved spatial and recognition memory, compared with mock-treated controls, suggesting that HDAC3 represents a potential drug target for several hallmarks of AD.
###
Article #18-05436 : "Inhibition of HDAC3 reverses Alzheimer's diseaserelated pathologies in vitro and in the 3xTg-AD mouse model," by Karolina Janczura et al.
MEDIA CONTACT : Claes Wahlestedt, University of Miami, FL; tel: 561-603-0072; e-mail: cwahlestedt@med.miami.edu
Proceedings of the National Academy of Sciences